Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …

Breast cancer, the most common type of cancer affecting women, encompasses a collection
of histologic (mainly ductal and lobular) and molecular subtypes exhibiting diverse clinical …

PURPOSE To update recommendations on appropriate use of breast cancer biomarker
assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast …

Importance Currently, predictive biomarkers for response to immune checkpoint inhibitor
(ICI) therapy in lung cancer are limited. Identifying such biomarkers would be useful to refine …

Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype
to treat. To date, therapies directed to specific molecular targets have rarely achieved …

Background Unresectable locally advanced or metastatic triple-negative (hormone-receptor–
negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is …

Recently, deep learning frameworks have rapidly become the main methodology for
analyzing medical images. Due to their powerful learning ability and advantages in dealing …

Purpose The aim of the current study was to conduct a pooled analysis of studies that have
investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage triple …

Background Understanding the impact of the tumor immune microenvironment and
BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint …

Importance Atezolizumab (anti–programmed cell death ligand 1 [PD-L1]) is well tolerated
and clinically active in multiple cancer types. Its safety and clinical activity in metastatic triple …